LensFlow AI·China Launch · Demo Environment
All systems healthy
LF

Supplier Performance

Compare distributors and design a resilient multi-supplier allocation.

Supplier

Shanghai Pharma

Overall
92
On-Time Delivery
96.4%
Avg Lead Time
42d
Emergency Success
92%
Fulfillment Acc.
99.1%
Stock Accuracy
98.7%
Cost / Fulfill
¥42
Coverage
National
Expiry Score
94
Supplier

Supplier B

Overall
81
On-Time Delivery
89.2%
Avg Lead Time
48d
Emergency Success
78%
Fulfillment Acc.
96.4%
Stock Accuracy
95.1%
Cost / Fulfill
¥36
Coverage
South + East
Expiry Score
86
Supplier

Manufacturer Direct

Overall
87
On-Time Delivery
92.8%
Avg Lead Time
60d
Emergency Success
70%
Fulfillment Acc.
99.6%
Stock Accuracy
99.2%
Cost / Fulfill
¥28
Coverage
Strategic Reserve
Expiry Score
98

Supplier Performance Comparison

Normalized score across key dimensions

Recommended Supplier Allocation

Multi-supplier strategy to reduce single-platform dependency

Primary National Distributor
Shanghai Pharma

Core SKUs across all regions. Compliance-heavy hospital channels and high-velocity Toric SKUs. Target 65% of fulfillment volume.

Regional Backup
Supplier B

South China and selected East China coverage. Emergency replenishment for stockout-risk SKUs. Target 20% of volume.

Strategic Reserve
Manufacturer Direct

Critical SKUs and new product launch control (EVO+ Toric). Long lead time but highest accuracy. Target 15% of volume.

Weighted Score
89.4
Single-Supplier Risk
Low
No supplier > 65%
Avg Blended Lead Time
9.1d
Emergency Coverage
3 of 4 regions

Supplier Switching Simulation 供应商切换模拟

What happens if N% of South China replenishment shifts from Shanghai Pharma to Supplier B

Shift to Supplier B30%
Allocation: Shanghai Pharma 70% · Supplier B 30%
Allocation ruleRegion-weighted, A-class first
Re-evaluate2 fulfillment cycles
Lead Time 交期
43.8d
1.8d
Cost Impact 成本
¥-0.2万
per cycle
Service Level Δ
-1.5 pp
Risk Level 风险
Low
Why consider switch

Shanghai Pharma lead time drift +3d in South China; service level dropped to 88%.

Tradeoff

Supplier B lower fulfillment accuracy (96.4%) and emergency success (78%).

Recommended split

30% to Supplier B for non-strategic SKUs in South China · keep A/X SKUs on Shanghai Pharma.

Supplier Action Tracker 履约动作

Status applied across the platform: Draft · Pending Approval · Approved · In Progress · Completed · Rejected

SupplierActionReasonOwnerDeadlineStatusExpected Impact
Shanghai PharmaRequest recovery planLead time +3d South ChinaSupplier Mgmt2026-06-12Pending ApprovalRestore SL 88% → 96%
Supplier BReallocate 30% S. ChinaBackup capacitySupply Planning2026-06-10ApprovedCoverage +18 pp
Manufacturer DirectReserve EVO+ Toric strategic stockLaunch protectionS&OP2026-07-01In ProgressLaunch SL 98%